Events

Upcoming Events

May 11-13, 2010
World Stem Cells & Regenerative Medicine Congress 2010
Conference - London, UK, presentation by Frederic Chereau; President and Chief Executive Officer, Pervasis Therapeutics

September 13-15, 2010
Stem Cells USA & Regenerative Medicine Congress 2010
Conference - Philadelphia, PA, Autologous vs. Allogeneic; panel presentation from Josh Hamermesh, SVP, Strategy and Corporate Development, Pervasis Therapeutics

Past Events

February 26, 2010
MHT 8th annual BioForum
Conference - Boston, MA, "High risks, high rewards: Avoiding the pitfalls of partnerships" panel presentation with Josh Hamermesh, SVP, Strategy and Corporate Development, Pervasis Therapeutics

January 26, 2010
Phacilitate 2010
Conference - Washington, DC, "Qualification of raw materials, impact of legacy materials" presentation from Jack Harvey, Director of Manufacturing, Pervasis Therapeutics

November 17, 2009
Stem Cell USA & Regenerative Medical Congress - Washington D.C.
Technology & Science Updates by Therapeutic Application "Inflammatory" panel presentation from Helen Marie Nugent, Ph.D.; Co-Founder and Vice President, Research and Development, Pervasis Therapeutics

October 27, 2009
Boston Biotech Research & Development Conference - Harvard Medical School, Cambridge, MA
"Cell Therapies, Redefined" presentation from Helen Marie Nugent, Ph.D.; Co-Founder and Vice President, Research and Development, Pervasis Therapeutics

June 8, 2009
13th Annual Goldman Sachs Global Healthcare Conference - New York, NY
Private Company Forum 3:30 pm Frederic Chereau; President and Chief Executive Officer, Pervasis Therapeutics, presented at the Goldman Sachs Global Healthcare Conference.

May 19-22, 2009
EuroPCR - Barcelona, Spain
Out-of-the-box innovations
"Percutaneous delivery of perivascular tissue engineered allogeneic endothelial cells minimizes intimal area and enhances vascular repair after endovascular peripheral interventions" presented by Helen Marie Nugent, Ph.D.; Co-Founder and Vice President, Research and Development, Pervasis Therapeutics